Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC boosted its holdings in Rezolute, Inc. (NASDAQ:RZLT) by 366.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 54,237 shares of the company’s stock after acquiring an additional 42,597 shares during the period. Cubist Systematic Strategies LLC owned 0.14% of Rezolute worth $233,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC purchased a new stake in Rezolute in the first quarter valued at $4,080,000. Federated Hermes Inc. raised its holdings in Rezolute by 11.1% in the 2nd quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company’s stock valued at $48,501,000 after buying an additional 1,125,000 shares during the period. Marshall Wace LLP acquired a new position in Rezolute in the second quarter valued at about $4,503,000. Vanguard Group Inc. boosted its stake in Rezolute by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after buying an additional 145,700 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Rezolute by 104.2% during the second quarter. Acadian Asset Management LLC now owns 184,502 shares of the company’s stock valued at $792,000 after acquiring an additional 94,156 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Rezolute Trading Up 0.6 %

NASDAQ:RZLT opened at $4.93 on Friday. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The firm has a market cap of $197.87 million, a PE ratio of -4.32 and a beta of 1.19. The stock has a fifty day moving average price of $4.65 and a 200 day moving average price of $3.94.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Equities analysts forecast that Rezolute, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Guggenheim began coverage on shares of Rezolute in a report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price objective on the stock. Maxim Group raised their price target on Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Friday, September 27th. BTIG Research increased their target price on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Finally, JMP Securities restated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a report on Friday, September 20th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.